Amgen files for U.S. approval of biosimilar to Humira
November 25, 2015 at 16:11 PM EST
Nov 25 (Reuters) - Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.
